GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cann Group Ltd (ASX:CAN) » Definitions » Float Percentage Of Total Shares Outstanding

Cann Group (ASX:CAN) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Cann Group Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cann Group's float shares is 0.00 Mil. Cann Group's total shares outstanding is 437.75 Mil. Cann Group's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cann Group's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cann Group's Institutional Ownership is 1.05%.


Cann Group Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cann Group's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/437.75
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cann Group (ASX:CAN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cann Group Ltd (ASX:CAN) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
262-276 Lorimer Street, Port Melbourne, VIC, AUS, 3207
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the company; the development and manufacture (via third party arrangements) of finished product formulations; and the pursuit and execution of various supply and offtake agreements with third parties.